Version 1
: Received: 1 June 2022 / Approved: 3 June 2022 / Online: 3 June 2022 (10:59:28 CEST)
How to cite:
Xu, H.; Wen, Y.; Jin, R.; Chen, H. Epigenetic Modifications and Targeted Therapy in Pediatric Acute Myeloid Leukemia. Preprints2022, 2022060046. https://doi.org/10.20944/preprints202206.0046.v1.
Xu, H.; Wen, Y.; Jin, R.; Chen, H. Epigenetic Modifications and Targeted Therapy in Pediatric Acute Myeloid Leukemia. Preprints 2022, 2022060046. https://doi.org/10.20944/preprints202206.0046.v1.
Cite as:
Xu, H.; Wen, Y.; Jin, R.; Chen, H. Epigenetic Modifications and Targeted Therapy in Pediatric Acute Myeloid Leukemia. Preprints2022, 2022060046. https://doi.org/10.20944/preprints202206.0046.v1.
Xu, H.; Wen, Y.; Jin, R.; Chen, H. Epigenetic Modifications and Targeted Therapy in Pediatric Acute Myeloid Leukemia. Preprints 2022, 2022060046. https://doi.org/10.20944/preprints202206.0046.v1.
Abstract
Acute myeloid leukemia (AML) is a hematological malignancy that is the culmination of genetic and epigenetic alterations in the hematopoietic progenitor cells, leading to uncontrolled proliferation at the expense of normal hematopoiesis and bone marrow exhaustion. Although the outcomes for pediatric AML have improved in recent decades, at least one third of children still have relapses. Recent studies have notably highlighted the important role of dysregulated epi-genetic mechanisms in myeloid leukemogenesis. Epigenetic modifications are frequently reversible compared to genetic alterations, thus providing opportunities for targeted epigenetic therapy. In this review, we summarize the landscape of epigenetic alterations and the progress to date in epigenetic targeted therapy, and focus on the future role of epigenetic abnormalities in predicting relapse and the precision therapy in pediatric AML.
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
